Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Short biography Lars Frelin Karolinska Institutet Short biography Name: Dr. Lars Frelin, Associate Professor in Virology. Birth data: March 25, 1977. Working address: Karolinska Institutet Department of Laboratory Medicine Division of Clinical Microbiology, F68 Karolinska University Hospital Huddinge S-141 86 Stockholm, Sweden P: +46-8-52483632, +46-70-4243001 F: +46-8-58587933 [email protected] www.ki.se Current scientific activities: Associate Professor at Karolinska Institutet, Department of Laboratory Medicine, Division of Clinical Microbiology, Karolinska University Hospital Huddinge. Principal investigator (PI) and group leader in the “Viral Hepatitis Research Group”. Main research focus is establishment and evaluation of in vivo and in vitro models of hepatitis B and C virus infection and vaccine development. Dr. Frelin has several national and international research collaborators with joint research projects. He has research funding from national and international foundations, government funds, and funds from pharmaceutical companies. Dr. Frelin is the Chairman of the International Committee for the Study Programme in Biomedical Laboratory Science and lecturer at Karolinska Institutet. Dr. Frelin is a frequent referee for several scientific journals. He has served as an evaluator for research grants and research positions at Karolinska Institutet. He is also a frequent member of thesis evaluation committees at Karolinska Institutet. Current and previous positions: 2013 – present Associate Professor in Virology, Karolinska Institutet. 2013 – present Chairman of the International Committee for the Study Programme in Biomedical Laboratory Science at Karolinska Institutet. 2013 – present Academic coordinator for a Linnaeus-Palme cooperation (student- and staff exchange) between Karolinska Institutet and Burapha University, Faculty of Allied Health Science, Chonburi, Thailand. 1 Short biography Lars Frelin Karolinska Institutet 2013 – present Member of the management team at Division of Clinical Microbiology, Karolinska Institutet. 2012 – present Consultant at ChronTech Pharma AB. 2011 – present Member of the Research Council at Department of Laboratory Medicine, Karolinska Institutet. 2010 – 2013 Senior Researcher, Karolinska Institutet. 2007 – 2009 Postdoctoral fellow, Karolinska Institutet. 2005 – 2006 Postdoctoral fellow, Vaccine Research Institute of San Diego, CA, USA and Scripps Research Institute, La Jolla, CA, USA. 2001 – 2004 PhD in Virology, Karolinska Institutet. 1997 – 2000 BSc in Molecular Biology, Södertörn University. Selected academic distinctions and other merits: *Riksföreningen hepatit C honorary award for the initiative for the research project: “Vertical and Horizontal Health Communication: Case Hepatitis C”, 2013. *Jonas Söderqvists award for basic research in virology and immunology, 2007. *Co-developed and tested the world’s first DNA vaccine delivered intramuscularly in combination with in vivo electroporation for treatment of chronic hepatitis C virus infected patients at Karolinska University Hospital Huddinge, 2007-2010. Selected Publications: Ahlén G, Holmström F, Petrova A, Alheim M, and Frelin L. Long-term functional duration of immune responses to HCV NS3/4A induced by DNA vaccination. Gene Therapy (2014);doi:10.1038/gt.2014.48. PMID: 24871581 Weiland O, Ahlén G, Diepolder H, Jung MC, Levander S, Fons M, Mathiesen I, Sardesai NY, Vahlne A, Frelin L, and Sällberg M. Therapeutic DNA vaccination using in vivo electroporation followed by standard of care therapy in patients with genotype 1 chronic hepatitis C. Molecular Therapy (2013);21(9):1796-805. PMID: 23752314 Fournillier A#, Frelin L#§, Jacquier E, Ahlén G, Brass A, Gerossier E, Holmström F, Broderick K, Sardesai N, Bonnefoy J-Y, Inchauspe G, and Sällberg M. A 2 Short biography Lars Frelin Karolinska Institutet heterologous prime/boost vaccination-strategy enhances the immunogenicity of therapeutic vaccines for hepatitis C virus. Journal of Infectious Diseases (2013);208(6):1008-1019. PMID: 23776192 # =AF and LF contributed equally to this work. § =corresponding author (LF). Rahbin N, Frelin L, Aleman S, Hultcrantz R, Sällberg M, and Brenndörfer ED. Non-structural 3 protein expression is associated with T cell protein tyrosine phosphatase and viral RNA levels in chronic hepatitis C patients. Biochemical and Biophysical Research Communications (2013); 433(1):31-5. PMID: 23454379 Holmström F, Pasetto A, Nähr V, Brass A, Kriegs M, Hildt E, Broderick KE, Chen M, Ahlén G, and Frelin L. A synthetic codon-optimized hepatitis C virus nonstructural 5A DNA vaccine primes polyfunctional CD8+ T cell responses in wild-type and NS5A-transgenic mice. Journal of Immunology (2013);190(3):111324. PMID: 23284053 Pasetto A, Frelin L, Aleman S, Holmström F, Brass A, Ahlén G, Brenndörfer ED, Lohmann V, Bartenschlager R, Sällberg M, Bertoletti A, and Chen M. TCRredirected human T cells inhibit hepatitis C virus replication: Hepatotoxic potential is linked to antigen specificity and functional avidity. Journal of Immunology (2012);189(9):4510-9. PMID: 23024278 Ahlén G, Chen A, Roe B, Falkeborn T, Frelin L, Hall WW, Sällberg M, and Söderholm J. Limited effect on viral fitness of mutations within the immunodominant HLA-A2-restricted epitope of the hepatitis C virus genotype 3 non-structural 3/4A protease. Journal of General Virology (2012);93(Pt 8):1680-6. PMID: 22592266 Pasetto A, Frelin L, Yasmeen A, Lohmann V, Bartenschlager R, Koh S, Magalhaes I, Maeurer M, Sällberg M, and Chen M. Generation of T cell receptors targeting a genetically stable and immunodominant cytotoxic T lymphocyte epitope within the hepatitis C virus non-structural 3 protein. Journal of General Virology (2012):93(Pt 2):247-58. PMID: 22071510 Lee BO, Jones JE, Peters CJ, Whitacre D, Frelin L, Hughes J, Kim W-J, and Milich DR. Identification of a unique double negative (DN) Treg cell population. Immunology (2011):134(4):434-47. PMID: 22044159 Malik-Riaz I, Chen A, Brass A, Ahlén G, Rahman M, Sällberg M, Qureshi JA, and Frelin L. A bi-functional hepatitis B virus core antigen chimera activates HBcAgspecific T cells and preS1-specific antibodies. Scandinavian Journal of Infectious Diseases (2012):44(1):55-9. PMID: 21933033 3